Aura Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
AURA$7.65-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(106,191) | $(86,919) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 1,129 | 1,223 |
| Accretion income on marketable securities | (1,546) | (4,659) |
| Other non-cash items | 27 | (5) |
| Stock-based compensation expense | 14,317 | 11,722 |
| Non-cash lease expense | 1,551 | 1,475 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 4,031 | (3,904) |
| Other long-term assets | 47 | (9) |
| Accounts payable | (846) | 482 |
| Accrued expenses and other liabilities | 4,131 | 1,577 |
| Operating lease liabilities | (1,392) | (788) |
| Net cash used in operating activities | (84,742) | (79,805) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (447) | (1,253) |
| Purchases of marketable securities | (83,958) | (59,103) |
| Proceeds from sale of marketable securities | — | (5) |
| Maturities of marketable securities | 120,000 | 129,182 |
| Net cash provided by investing activities | 35,595 | 68,821 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 1,010 | 1,418 |
| Proceeds from issuance of common stock from follow-on offering, net of issuance costs | 46,517 | — |
| Proceeds from issuance of pre-funded warrants from follow-on offering, net of issuance costs | 14,156 | — |
| Proceeds from issuance of common stock warrants from follow-on offering, net of issuance costs | 9,254 | — |
| Proceeds from issuance of common stock under ATM facility, net of issuance costs | 6,054 | — |
| Proceeds from ESPP purchases | 164 | 177 |
| Net cash provided by financing activities | 77,155 | 1,595 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 28,008 | (9,389) |
| Effect of exchange rate changes on cash and cash equivalents | (186) | — |
| Cash, cash equivalents and restricted cash at beginning of period | 32,461 | 41,850 |
| Cash, cash equivalents and restricted cash at end of period | $60,283 | $32,461 |
| Supplemental disclosure of cash flow information: | ||
| Purchases of property and equipment in accounts payable and accrued expenses and other liabilities | $91 | $35 |
| The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands): | ||
| December 31, | ||
| 2025 | 2024 | |
| Cash and cash equivalents, end of period | $59,515 | $31,693 |
| Long-term restricted cash, end of period | 768 | 768 |
| Cash, cash equivalents and restricted cash at end of period | $60,283 | $32,461 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.